PHARMASEAL, a new provider of clinical trial management and governance solutions, announced that a U.S. health outcomes and technology company has selected Engility Clinical Trial Management system for the management and oversight of its clinical trial programs.
In the field of health outcomes and technology, companies are looking to leverage big clinical data and artificial intelligence (AI) to better understand, compare, and predict patient outcomes. The task of combining real-world evidence (RWE), clinical registries and AI technologies can be challenging. Engility was chosen to provide a validated system for managing clinical trial information, reduce data duplication and improve trial collaboration.
Engility CTMS is a modern cloud-based enterprise trial management system used by medical device, biopharmaceutical, and CRO’s to aim to improve how they manage and control clinical trials. With support for multiple sourcing models, flexible trial designs including centralized/virtual/remote trials, Engility CTMS is ideally placed to support good clinical practice (GCP E6) requirements and spearhead clinical operational process improvements.
Daljit Cheema, Founder and CEO of PHARMASEAL commented, “We are delighted that our integrated enterprise platform, Engility, has been selected and licensed to help drive new insights for this company. Our innovative platform utilizes advanced engineering offering enterprise management with rapid deployment, an intuitive user interface and interoperability with other eClinical applications to optimize governance and oversight. At PHARMASEAL, we have the vision to create smarter technologies for the improvement of human health and we are excited to see what possibilities emerge from this collaboration for transforming the future of healthcare.”